Redfield Robert R, Gupta Meera, Rodriguez Eduardo, Wood Alexander, Abt Peter L, Levine Matthew H
1 Department of Surgery, Hospital of the University of Pennsylvania, Philadelphia, PA. 2 Division of Transplant Surgery, Department of Surgery, Hospital of the University of Pennsylvania, Philadelphia, PA.
Transplantation. 2015 Feb;99(2):416-23. doi: 10.1097/TP.0000000000000332.
The waiting time for deceased donor renal transplantation in the United States continues to grow. Retransplant candidates make up a small but growing percentage of the overall transplant waiting list and raise questions about the stewardship of scarce resources. The utility of renal transplantation among individuals with two prior renal transplants is not described in the literature, and we thus sought to determine the survival benefit associated with a third kidney transplant (3KT).
Multivariable Cox regression models were created to determine characteristics associated with 3KT outcomes and the survival benefit of 3KT among recipients wait listed and transplanted within the United States between 1995 and 2009.
A total of 4,334 patients were waitlisted for a 3KT and 2,492 patients received a 3KT. In a multivariate analysis, 3KT demonstrated an overall patient survival benefit compared to the waitlist (hazards ratio, 0.379; 95% confidence interval, 0.302-0.475; P<0.001) for those awaiting their first, second, or third kidney transplants, although an inferior graft outcome compared to first kidney transplants. The time to survival benefit did not accrue until 8 months after transplantation. In addition, we found that the duration of second graft survival was predictive of third graft survival, such that second graft survival beyond 5 years is associated with superior 3KT graft survival. Second graft loss in 30 days or less was not associated with inferior 3KT graft survival.
A 3KT achieves a survival benefit over remaining on the waitlist, although is associated with inferior graft outcomes compared to first kidney transplants. Graft survival of the second transplant beyond 5 years is associated with superior 3KT graft survival.
在美国,已故捐赠者肾移植的等待时间持续延长。再次移植候选者在整个移植等待名单中所占比例虽小但呈上升趋势,这引发了关于稀缺资源管理的问题。文献中未描述有过两次肾移植的个体进行肾移植的效用,因此我们试图确定第三次肾移植(3KT)的生存获益情况。
建立多变量Cox回归模型,以确定与3KT结局相关的特征以及1995年至2009年在美国等待名单上并接受移植的受者中3KT的生存获益情况。
共有4334例患者被列入3KT等待名单,2492例患者接受了3KT。在多变量分析中,对于等待首次、第二次或第三次肾移植的患者,与等待名单相比,3KT显示出总体患者生存获益(风险比,0.379;95%置信区间,0.302 - 0.475;P<0.001),尽管与首次肾移植相比移植结局较差。生存获益直到移植后8个月才显现。此外,我们发现第二次移植的存活时间可预测第三次移植的存活情况,即第二次移植存活超过5年与3KT移植存活情况较好相关。30天内或更短时间内第二次移植失败与3KT移植存活情况较差无关。
与留在等待名单上相比,3KT可实现生存获益,尽管与首次肾移植相比移植结局较差。第二次移植存活超过5年与3KT移植存活情况较好相关。